Rekvina Laboratories Limited (BOM:526075)
49.90
-1.01 (-1.98%)
At close: Sep 25, 2026
Rekvina Laboratories Revenue
Rekvina Laboratories had revenue of 6.69M INR in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 19.34M. In the fiscal year ending March 31, 2026, Rekvina Laboratories had annual revenue of 12.65M.
Revenue (ttm)
19.34M
Revenue Growth
n/a
P/S Ratio
28.68
Revenue / Employee
3.87M
Employees
5
Market Cap
554.68M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 12.65M | - | - |
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Mangalam Drugs & Organics | 2.32B |
| Rajnish Wellness | 1.68B |
| ANG Lifesciences India | 835.87M |
| Source Natural Foods and Herbal Supplements | 796.24M |
| Shelter Pharma | 731.34M |
| Onyx Biotec | 694.69M |
| Panjon | 492.78M |
| Phaarmasia | 486.17M |